Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hybridon HYBN, for discussion of antisense drugs. -- Ignore unavailable to you. Want to Upgrade?

To: priceguy who wrote (38)	7/11/1999 6:10:00 PM
From: JMarcus	Respond to of 42

You can find links to past press releases by running a search for HYBN on www.biospace.com. The company has a website at www.hybridon.com, but I couldn't access it just now (first time I've tried in recent memory) and don't know the reason. I'm not aware of any chatrooms (other than ours) that follow HYBN. I cribbed the following info from HYBN's 7/7/99 prospectus, which you can find through www.FreeEdgar.com: HYBN's lead drug candidate is GEM(R) 231, which completed its Phase I trial last fall. GEM(R) 231 is designed to reduce the production of the harmful PKA (protein kinase A) type I (associated with developing fetuses and cancerous tumors) without interfering with the production of PKA type II (necessary to health in normal adults). Hybridon is currently conducting additional Phase II and Phase 1/II studies with GEM(R) 231 in patients with solid tumors that had not been cured by prior therapy. In addition, Hybridon has begun the first in a series of Phase I/II trials treating patients with solid tumors with GEM(R) 231 in combination with other anti-cancer therapies, such as Taxol(R), Taxotere(R) or radiation therapy. Hybridon has also completed a Pilot Phase I clinical study in Europe of GEM(R) 92, Hybridon's advanced chemistry compound for the treatment of HIV-1 infection and AIDS. GEM(R) 92 was detected in the blood after both oral dosing and injection, suggesting that it may be possible to develop GEM(R) 92 as an oral drug. Hybridon believes this was the first study of the oral administration of an antisense molecule to humans. In in-vitro studies, beneficial effects were observed when GEM(R) 92 was used in combination with several marketed AIDS drugs. Importantly, both its medicinal approach and genetic target are unique, in that no antisense drug has been approved for the treatment of AIDS, and no other drug has the same target on the HIV-1 genome. The company is seeking partners to fund the further clinical development of these drugs. Marc